Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of TRK-250 in Idiopathic Pulmonary Fibrosis
NCT03727802Phase 1Completed
- Sponsor
- Toray Industries
- Start
- Nov 2018
- Primary completion
- Apr 2022
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TRK-250 in idiopathic pulmonary fibrosis (IPF) (3 arms), sponsored by Toray Industries. Primary endpoint: Incidence and Severity of Adverse Events. Started Nov 2018; status: completed.
02
Drugs
TRK-250
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT03727802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03727802.